Neovacs S.A. (ALNEV.PA) Stock Price

€0.86 0%

Sign up
to add to portfolio

AI Score

Sell

  • Alternative

    4

  • Fundamental

    1

  • Technical

    2

Our AI score evaluates a company's performance on a scale from 0 to 10 by analyzing alternative data points — web traffic, app downloads, job postings, etc - along with financial health and technical signals. Scores below 4 project bearish performance, while scores above 6 project bullish performance.

Sign up to get access to more historical data and insights on Neovacs S.A., AI stock picks, stock alerts and much more.

Sign up

ALNEV.PA AI Stock Analysis

AI stock analysis for ALNEV.PA is missing at the moment.

Our AI stock analysis reviews financial data, technical analysis, and alternative data insights to project stock performance. For example, analyzing a company like Neovacs S.A. (ALNEV.PA) provides a clear summary of future projections. Gain the edge you need to make confident, data-driven investment decisions.

Sign up and become a member to get access to AI stock analysis.

Sign up

Neovacs S.A. (ALNEV.PA) Price Prediction

Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of Neovacs S.A. (ALNEV.PA), currently trading at €0.86, will... Sign up to access price prediction.

Disclaimer:
This prediction is provided for informational purposes only and does not constitute financial advice. Market conditions are subject to change, and past performance is not indicative of future results. Please conduct your own research or consult a professional before making investment decisions.

About ALNEV.PA

LSE

Similar Stocks

VLA.PA Valneva SE
VLA.PA		 €5.05
2.4%
5
TUB.BR Financière de Tubize SA
TUB.BR		 €160.6
0.4%
8
OSE.PA OSE Immunotherapeutics SA
OSE.PA		 €6.32
0.5%
6
UCB.BR UCB SA
UCB.BR		 €197.3
0.9%
6
IPH.PA Innate Pharma S.A.
IPH.PA		 €2.01
1.9%
5

News

No news articles.

ALNEV.PA Alternative Data

Web Traffic

Neovacs S.A. receives an estimated 2579 monthly visitors to neovacs.com.

  • Web Traffic

    2579

  • Change from Previous Month

    77.6%

  • 3 Month Change

    66.2%

  • YoY Change

    66.2%

Twitter Followers

Neovacs S.A. has 887 Twitter Followers on its main Twitter (also known as X) account, which is down by -0.1% over the last month.

  • Twitter Followers

    887

  • Daily Change

    0%

  • 1 Month Change

    0.1%

  • 3 Month Change

    0.2%

  • YoY Change

    0.2%

Youtube Subscribers

Neovacs S.A. has 27 subscribers on its main Youtube channel.

  • Youtube Subscribers

    27

  • Daily Change

    0%

  • 1 Month Change

    0%

  • 3 Month Change

    0%

  • YoY Change

    0%

Job Postings

Neovacs S.A. currenly has an estimated 0 open job postings.

  • Job Postings

    0

  • Daily Change

    0%

  • 1 Month Change

    0%

  • 3 Month Change

    0%

  • YoY Change

    0%

LinkedIn Followers

1,431 are following Neovacs S.A. on LinkedIn, up by 1.1% over the last month.

  • LinkedIn Followers

    1431

  • Daily Change

    1.1%

  • 1 Month Change

    1.1%

  • 3 Month Change

    3.8%

  • YoY Change

    3.8%

LinkedIn Employees

According to LinkedIn, Neovacs S.A. has 18 employees.

  • LinkedIn Employees

    18

  • Daily Change

    0%

  • 1 Month Change

    0%

  • 3 Month Change

    0%

  • YoY Change

    0%

Reddit Mentions

Neovacs S.A. has been mentioned an estimated 0 times in investment subreddits on Reddit over the last 24 hours.

  • Reddit Mentions

    0

  • Daily Change

    0%

  • 1 Month Change

    0%

  • 3 Month Change

    0%

News Mentions

Neovacs S.A. was mentioned 0 times in the news yesterday.

  • News Mentions

    0

  • Daily Change

    0%

  • 1 Month Change

    0%

  • 3 Month Change

    0%

  • YoY Change

    0%

ALNEV.PA Financials

ALNEV.PA Key Metrics

  • Total Revenue

    €250.3K

  • Net Income

    -€31M

  • Earnings per Share

    -€3.32

  • Free cash flow

    -€3M

  • EBITDA

    -€31.3M

  • EBITDA Ratio

    -125.255

  • Total Assets

    €38.9M

ALNEV.PA 2-year Revenue & Income
ALNEV.PA 2-year Free Cash Flow

ALNEV.PA Technicals

ALNEV.PA SMA
ALNEV.PA RSI

FAQ

What's the current price of Neovacs S.A. (ALNEV.PA) Stock?
The price of an Neovacs S.A. (ALNEV.PA) share is €0.86.

What's the market cap of Neovacs S.A.?
The current market cap of Neovacs S.A. is 409898.

Should I buy or sell ALNEV.PA?
Neovacs S.A. exhibits several negative alternative data signals, leading us to expect continued underperformance in the coming months. As a result, we maintain a negative outlook on this stock.

Is Neovacs S.A. a good investment?
Considering the fundamentals, technical analysis, and alternative data insights, it may not be the best time to invest in Neovacs S.A. stock. There are several bearish signals and market challenges that could negatively impact Neovacs S.A.'s future performance, suggesting that caution should be exercised before making any investment decisions.

Is now a good time to buy Neovacs S.A. (ALNEV.PA) Stock?
Based on an analysis that includes fundamentals, technical analysis, and alternative data insights, it may not be the best time to buy Neovacs S.A. stock right now, as the outlook appears bearish.

What are some stocks similar to Neovacs S.A. (ALNEV.PA) that investors often compare it to?
Neovacs S.A. (ALNEV.PA) is often compared to similar stocks such as Valneva SE, Financière de Tubize SA, OSE Immunotherapeutics SA, UCB SA and Innate Pharma S.A..

What is the forecast for Neovacs S.A.'s stock price in 2026?
Using a mix of financial analysis, technical indicators, and alternative data, we forecast Neovacs S.A.'s stock price to be around €0.798 in 2026. Starting from the current price of €0.86, this represents a 7.2% change in price, indicating a bearish outlook for the stock.

How to buy Neovacs S.A. (ALNEV.PA) Stock?
Neovacs S.A. stock is available for purchase through numerous brokerage firms, including online platforms. Investors can also buy Neovacs S.A. shares via trading apps on their smartphones or by utilizing services like robo-advisors for automated investing.